Lipid oxidation product (LOP)

Lipid oxidation products form when lipids, especially polyunsaturated fatty acids (PUFAs), undergo oxidative attack by reactive oxygen species or free radicals, leading to the production of primary (hydroperoxides) and secondary (aldehydes such as malondialdehyde and 4-hydroxy-2-nonenal) breakdown products[1][2][3][9]. These molecules are highly reactive and can covalently modify proteins, DNA, and other cellular components, resulting in cytotoxic effects, mutagenesis, and inflammatory responses. The accumulation of lipid oxidation products is implicated in the pathogenesis of various conditions, including atherosclerosis, cancer, metabolic syndrome, and age-related diseases[2][4][7]. While they are not direct therapeutic targets, their formation is typically suppressed or mitigated by antioxidants. Key Points: - Not a target in the classic pharmacological sense (not a receptor, enzyme, transporter, etc.) - Includes a diverse array of molecules, including hydroperoxides, aldehydes (MDA, 4-HNE), and ox-LDL - Serve as biomarkers for oxidative stress rather than direct drug targets - Suppression by antioxidants (e.g., vitamin E, vitamin C) is a key therapeutic and preventative strategy[1]

Other names

lipid peroxidation productoxidized lipidsecondary lipid oxidation productLOPlipid peroxide

Antioxidants scavenge free radicals to prevent LOP formation rather than directly acting on LOPs